Krystal Biotech President Krishnan Suma sold 25,000 shares at prices ranging from $354.54 to $366.56 per share. The transaction matters to investors because Suma retained 1,302,145 Krystal Biotech shares after the sale, leaving a disclosed post-transaction ownership figure.
Key Highlights
- Krishnan Suma completed the sale through 13 separate transactions.
- The transactions took place on 4 September 2026.
- Suma owned 1,302,145 Krystal Biotech shares after the transactions.
Regulatory Filing Krishnan Suma, President, R&D of Krystal Biotech, Inc.
(NASDAQ: KRYS) filed a Form 4 with the SEC. The filing concerns transactions in Krystal Biotech, Inc. shares and identifies the company as NASDAQ: KRYS.
Share Transactions On 4 September 2026, Suma sold a total of 25,000 Krystal Biotech, Inc.
shares across 13 separate transactions. All 13 transactions used SEC transaction code S, with prices ranging from $354.54 to $366.56 per share.
Reported Ownership Following
these transactions, Krishnan Suma owned 1,302,145 shares of Krystal Biotech, Inc. The filing identifies Suma as the company’s President, R&D and reports the post-transaction ownership figure after the 25,000-share sale.
FAQs
Q: How many Krystal Biotech shares did Krishnan Suma sell?
A: Krishnan Suma sold 25,000 Krystal Biotech shares. The sales occurred across 13 separate transactions at prices ranging from $354.54 to $366.56 per share.
Q: When did the Krystal Biotech share sale occur?
A: The Krystal Biotech transactions took place on 4 September 2026. The sale involved 25,000 shares owned by President of R&D Krishnan Suma.
Q: How many shares did Suma own after selling Krystal Biotech stock?
A: Krishnan Suma owned 1,302,145 Krystal Biotech shares after the transactions. The disclosed ownership figure follows the sale of 25,000 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.